Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.04
+$0.16 · +2.33%
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Previous close
$7.04
+$0.16 · +2.33%
After-hours
$7.05
+$0.01 · +0.14%
Sep 16, 7:34 PM ET
Regular session · ET · Market data may be delayed.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Day range
Current $7.04
52-week range
Current $7.04
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
51
Mixed
Risk
47
Elevated Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Day range
Current $7.04
52-week range
Current $7.04
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cost of goods sold | 647K USD | 668K USD | — | — |
| Gross profit | −647K USD | −668K USD | — | — |
| Research and development | 60.26M USD | 57.29M USD | 40.63M USD | 34.61M USD |
| Selling, general, and administrative | 28.72M USD | 13.27M USD | 9.71M USD | 6.77M USD |
| Operating expenses | 88.34M USD | 69.89M USD | 50.33M USD | 41.37M USD |
| Interest income | 13.3M USD | 8.17M USD | 2.77M USD | 1.13M USD |
| Depreciation and amortization | 647K USD | 668K USD | 583K USD | 122K USD |
| Operating income | −88.98M USD | −70.56M USD | −50.33M USD | −41.37M USD |
| Net income | −75.27M USD | −61.69M USD | −47.26M USD | −40.24M USD |
Company facts updated Sep 17, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$27.40
289.20% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI5.64M0.00%2.3T USD0.03%$371.26-0.42%
State Street SPDR S&P Biotech ETFXBI4.78M0.04%10.5B USD0.35%$154.18+0.10%
iShares Russell 2000 ETFIWM3.37M0.00%79.89B USD0.19%$283.92-0.43%
Vanguard U.S. Momentum Factor ETFVFMO2.42M0.12%1.9B USD0.13%$224.13-0.13%
iShares Biotechnology ETFIBB1.39M0.01%10.45B USD0.44%$202.4+0.20%
iShares Russell 2000 Growth ETFIWO1.19M0.01%14.31B USD0.24%$361.11-0.03%
Vanguard Extended Market ETFVXF1.01M0.00%95.4B USD0.05%$234.39-0.32%
Vanguard Russell 2000 ETFVTWO637.97K0.00%18B USD0.06%$115.07-0.43%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard U.S. Momentum Factor ETFVFMOiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
